Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 651 to 660 of 1090 total matches.
Amprenavir: A New HIV Protease Inhibitor
The Medical Letter on Drugs and Therapeutics • Jul 16, 1999 (Issue 1057)
, increased aminotransferase activity and altered body fat distribution have been reported.
DRUG INTERACTIONS ...
Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least four years old.
Elbasvir/Grazoprevir (Zepatier) for Hepatitis C
The Medical Letter on Drugs and Therapeutics • Feb 29, 2016 (Issue 1489)
drug interactions. The level of evidence supporting
use of simeprevir plus sofosbuvir is the same ...
The FDA has approved Zepatier (Merck), a fixed-dose
combination of two direct-acting antiviral
agents — elbasvir, an NS5A inhibitor, and grazoprevir,
an NS3/4A protease inhibitor — for oral treatment
of chronic hepatitis C virus (HCV) genotype 1 or 4
infection.
Comparison Table: Some Nonopioid Analgesics for Pain (online only)
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
Drug Interactions
May decrease effectiveness of diuretics, beta
blockers, ACE inhibitors, and some ...
View the Comparison Table: Some Nonopioid Analgesics for Pain
A New Amphetamine Oral Suspension (Adzenys ER) for ADHD (online only)
The Medical Letter on Drugs and Therapeutics • Jun 18, 2018 (Issue 1549)
, psychosis, drug dependence,
or alcoholism.
DRUG INTERACTIONS – Adzenys ER is contraindicated
for use ...
The FDA has approved an extended-release oral
suspension formulation of amphetamine (Adzenys ER
– Neos) for treatment of attention deficit hyperactivity
disorder (ADHD) in patients ≥6 years old. The same
extended-release amphetamine product is available
as an orally disintegrating tablet and is marketed as
Adzenys XR-ODT. Another extended-release oral
suspension formulation of amphetamine, Dyanavel
XR, was approved earlier.
Bedaquiline (Sirturo) for Multidrug-Resistant Tuberculosis
The Medical Letter on Drugs and Therapeutics • Aug 19, 2013 (Issue 1423)
in animals; no adequate studies in
women) for use during pregnancy.
DRUG INTERACTIONS — Bedaquiline ...
Bedaquiline (bed ak' wi leen; Sirturo – Janssen), a
diarylquinoline antimycobacterial, has been given
accelerated approval by the FDA as an orphan drug
for use in addition to other drugs for treatment of adults
with multidrug-resistant pulmonary tuberculosis
(MDR-TB). It is the first drug approved specifically to
treat MDR-TB.
A Topical Carbonic Anhydrase Inhibitor For Glaucoma
The Medical Letter on Drugs and Therapeutics • Sep 01, 1995 (Issue 956)
well tolerated, but
they are absorbed systemically and can cause adverse drug interactions, cardiac ...
Dorzolamide hydrochloride (Trusopt - Merck), a thienothio-pyran-2-sulfonamide carbonic anhydrase inhibitor, was recently approved by the US Food and Drug Administration in a 2% ophthalmic solution for treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Daclatasvir (Daklinza) for HCV Genotype 3 Infection
The Medical Letter on Drugs and Therapeutics • Oct 12, 2015 (Issue 1479)
women. Daclatasvir has been detected in the
milk of lactating rats.
DRUG INTERACTIONS — Severe ...
The FDA has approved daclatasvir (Daklinza – BMS),
an oral direct-acting antiviral drug, for use with
sofosbuvir (Sovaldi) for treatment of chronic hepatitis
C virus (HCV) genotype 3 infection. Daclatasvir is
the first drug approved for this indication that does
not require the addition of interferon or ribavirin. It is
approved in Japan and Europe in combination with
other drugs for treatment of HCV genotypes 1-4.
Low-Dose Meloxicam (Vivlodex) for Osteoarthritis Pain
The Medical Letter on Drugs and Therapeutics • Mar 14, 2016 (Issue 1490)
to an increased incidence of stillbirth.
DRUG INTERACTIONS — NSAIDs may decrease
the effectiveness of diuretics ...
The FDA has approved Vivlodex (Iroko), a low-dose
formulation of the nonsteroidal anti-inflammatory drug
meloxicam (Mobic, and generics), for management of
osteoarthritis pain. According to the manufacturer, the
new formulation aligns with stronger FDA warnings
about the cardiovascular risks of NSAIDs and the
recommendation to use the lowest possible doses of
these drugs.
Panobinostat (Farydak) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015 (Issue 1475)
.
DRUG INTERACTIONS — Panobinostat is a substrate
of CYP3A and P-glycoprotein (P-gp) and an inhibitor ...
The FDA has approved panobinostat (Farydak –
Novartis), an oral histone deacetylase (HDAC) inhibitor,
for use in combination with bortezomib (Velcade) and
dexamethasone for treatment of patients with multiple
myeloma who have received at least 2 prior therapies
including bortezomib and an immunomodulatory
drug. It is the first HDAC inhibitor to be approved for
this indication.
Memantine for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Sep 15, 2003 (Issue 1165)
The Medical Letter
On Drugs and Therapeutics
www.medicalletter.org
Published by The Medical ...
Memantine hydrochloride, which has been used to treat dementia in Germany (Axura Merz) since 1982, has become the latest word-of-mouth miracle drug for Alzheimer's disease in the US (G Kolata, NY Times, June 15, 2003). Forest Laboratories has submitted a New Drug Application to the FDA for memantine. This review describes the standard treatment for Alzheimer's Disease, mechanism of action, clinical studies, adverse effects and dosage. Also included are sections on availability of the drug and how some people are obtaining memantine from abroad.